Recombinant Proteins Manufacturing Services Market to Grow with a CAGR of 7.21% through 2029

Rise in advancements in biotechnology are expected to drive the Global Recombinant Proteins Manufacturing Services Market growth in the forecast period, 2025-2029. 

According to TechSci Research report, “Recombinant Proteins Manufacturing Services Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Recombinant Proteins Manufacturing Services Market stood at USD 3.06 Billion in 2023 and is anticipated to grow with a CAGR of 7.21% through 2029. Recombinant Proteins Manufacturing Services are indispensable for the biotechnology and pharmaceutical sectors, bolstering research and development endeavors across multiple domains, including oncology, immunology, and infectious diseases. A primary catalyst driving the global market for these services is the rapid expansion of the biopharmaceutical industry. Biopharmaceuticals, such as monoclonal antibodies, therapeutic proteins, and vaccines, are gaining prominence in treating diverse ailments like cancer, autoimmune disorders, and infectious diseases. With the industry's growth, there arises an escalated demand for recombinant proteins essential in drug development, clinical trials, and therapeutic manufacturing.

Technological advancements have significantly propelled the recombinant proteins market, particularly in gene editing, cell line development, and expression systems. These innovations have enhanced the efficiency and cost-effectiveness of recombinant protein production, facilitating the development of novel therapeutic proteins and enabling the scaled-up production of established biopharmaceuticals.

The prevalence of chronic diseases, including cancer, diabetes, and cardiovascular disorders, remains a global concern. Recombinant proteins play a pivotal role in devising innovative treatments for such conditions, thereby driving the demand for manufacturing services to support research and drug development efforts. The COVID-19 pandemic underscored the urgency of rapid vaccine development and therapeutic antibody production, with recombinant proteins manufacturing services playing a crucial role in their production. This experience has accelerated research and development in vaccine manufacturing, rendering recombinant proteins indispensable in pandemic preparedness and response.

The paradigm shift towards personalized medicine and targeted therapies has further amplified the demand for recombinant proteins in the biopharmaceutical sector. Tailored treatments, often based on individual genetic profiles, necessitate specific proteins for diagnosis and treatment. Recombinant proteins assume a pivotal role in crafting these highly targeted therapeutic solutions, given their ability to be precisely engineered to interact with specific cellular targets.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Recombinant Proteins Manufacturing Services Market”

The Global Recombinant Proteins Manufacturing Services Market is segmented into service type, host cell, end-user, regional distribution, and company. 

Based on End-user, Pharmaceutical & Biotechnology Companies have emerged as the dominating segment in the Global Recombinant Proteins Manufacturing Services Market in 2023. Pharmaceutical & biotechnology enterprises are chiefly focused on the development and production of biopharmaceutical goods for widespread commercial dissemination. These products encompass monoclonal antibodies, therapeutic proteins, vaccines, and gene therapies, all of which rely heavily on recombinant proteins as fundamental constituents. Consequently, these firms require a consistent and reliable supply of top-tier recombinant proteins to sustain their product pipelines. Unlike academic and research institutes, these companies often require recombinant proteins on a significantly larger scale. Commercial-scale production demands substantial quantities of recombinant proteins to fulfill market needs, thereby inherently fueling the demand for manufacturing services capable of large-scale and efficient production.

Based on Region, Asia Pacific have emerged as the fastest growing region in the Global Recombinant Proteins Manufacturing Services Market in 2023. With increasing disposable incomes and enhanced accessibility to healthcare services, healthcare expenditure is on the rise throughout the Asia Pacific region. This surge in spending prompts a heightened demand for cutting-edge healthcare offerings, including biopharmaceuticals, consequently amplifying the necessity for manufacturing services catering to recombinant proteins. Numerous nations across the Asia Pacific region are placing significant emphasis on advancing research and development within the biotechnology and pharmaceutical sectors, aiming to address healthcare hurdles and spur innovation. This prioritization of R&D activities fuels the need for manufacturing services specializing in recombinant proteins, essential for supporting endeavors in drug discovery and development. Collaborative ventures between domestic enterprises and international corporations in the Asia Pacific region are facilitating the transfer of technology and knowledge exchange, thereby fostering growth in the market for manufacturing services related to recombinant proteins. These partnerships facilitate access to state-of-the-art manufacturing technologies and expertise, consequently propelling further expansion within the market.

 

Major companies operating in Global Recombinant Proteins Manufacturing Services Market are:

• Lonza Group Ltd. 
• Boehringer Ingelheim International GmbH
• FUJIFILM Diosynth Biotechnologies USA, Inc.
• Merck KGaA
• Bruker Corporation
• Sino Biological, Inc.
• GenScript Biotech Corporation
• Kaneka Corporation 
• Polyplus Transfection S.A. 
• Boster Biological Technology Co., Ltd.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Global Market for Recombinant Proteins Manufacturing Services is set for substantial expansion in the foreseeable future. The escalating requirement for biologics, personalized medicine, and cutting-edge therapies, encompassing gene and cell-based treatments, is anticipated to drive up the demand for recombinant proteins. Moreover, the surge in chronic diseases and the necessity for accurate diagnostics and efficacious treatments will further fuel the growth of this sector. Continued advancements in biotechnology, marked by enhanced expression systems, high-throughput technologies, and process optimization, will additionally augment the efficiency and cost-effectiveness of recombinant protein manufacturing”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Recombinant Proteins Manufacturing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type (Pre-clinical & Clinical Services, Commercial Production Services), By Host Cell (Mammalian Cells, Bacterial Cells, Insect Cells, Yeast & Fungi, Others), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Recombinant Proteins Manufacturing Services Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Recombinant Proteins Manufacturing Services Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com